Search Results - "Van Wilder, P"

Relative efficacy and effectiveness assessment of new pharmaceuticals in three EU member states: current practices and outcome agreement between Belgium, the Netherlands and France by Van Wilder, P. B., Bormans, V. V., Dupont, A. G.

“…Purposes Relative efficacy and effectiveness assessment (REA) of a pharmaceutical product is critical in reimbursement decisions. The Pharmaceutical Forum…”
Get full text

REIMBURSEMENT OF MEDICINES IN BELGIUM: ROLE OF EVIDENCE-BASED MEDICINE by Van Wilder, P.B., Dupont, A.G.

“…The European Transparency Directive (TD) requires that pricing and reimbursement decisions must be taken in a transparent, objective and verifiable way with…”
Get full text

Use Of Factor Analysis To Obtain Independent Health Performance Indicators by Van, Wilder P, Bormans, V, Leemans, E

Get full text

HT1 Effectiveness, Efficiency and Budget Impact Affect The Belgian Drug Reimbursement Decision (DRD) by Bormans, V, Van Wilder, P

Get full text

Pharmaceutical Reimbursement Of Innovative Medicinal Products In Belgium by Van Wilder, P, Bormans, V

Get full text

PHP160 - Pharmaceutical Reimbursement Of Innovative Medicinal Products In Belgium by Van Wilder, P, Bormans, V

Get full text

HSD19 Which Elements Determine Prescribing Decisions for Off-Patent Biological Medicines in Belgium? A Qualitative Study by Vandenplas, Y, Simoens, S, Van Wilder, P, Vulto, A, Turk, F, Huys, I

Get full text

HPR116 The Impact of Policy Measures to Increase the Uptake of Biosimilar Medicines in Belgium: A Nationwide Interrupted Time Series Analysis by Vandenplas, Y, Simoens, S, Van Wilder, P, Vulto, A, Huys, I

Get full text

POSB382 Perceptions about Biosimilar Medicines Among Belgian Ambulatory Care Patients by Vandenplas, Y, Barbier, L, Simoens, S, Van Wilder, P, Vulto, A, Huys, I

Get full text

PBI32 Fulfilling the Potential of Best-VALUE Biological Medicines in Belgium by Vandenplas, Y., Simoens, S., Van Wilder, P., Vulto, A., Huys, I.

Get full text

PHP251 - Use Of Factor Analysis To Obtain Independent Health Performance Indicators by Van, Wilder P., Bormans, V., Leemans, E.

Get full text

Benefits of improving air quality in the Brussels-Capital Region, Belgium. A prospective study on premature death and related economic cost using AirQ by J, Andrieux, P, Van Wilder, D, Mazina, C, Bouland

Get full text

Ranitidine nocte (Rhs) v ranitidine mane and nocte (Rbid) by Plas, J, Van Wilder, Ph

Get full text

PHP29 PATHOLOGY RELATED DIFFERENCES INVARIANCE OF DRUG INSURANCE COST IN HOSPITAL STAYS: FEASIBILITY OF FIXED FUNDING IN PATHOLOGIES WITH REDUCED COST VARIANCE by Van Wilder, P, Verplanken, P

Get full text

PIN30 OBSERVATIONAL STUDY ON THE “REAL LIFE” PRACTICE AND COST OF ANTIBIOTIC (AB) MEDICATION IN PNEUMOCOCCAL PNEUMONIA PATIENTS: PARENTERAL VERSUS STEP DOWN THERAPY (SDT) by Verplanken, P, Van Wilder, P

Get full text

PHP27 PREDICTIVE VALUE OF PHARMACEUTICAL TREATMENT (PT) COST AND LENGTH OF STAY (LOS) ON TOTAL HOSPITAL (TH) COST USING THE MINIMUM BASIC DATA SET (MBDS) by Van Wilder, P, Verplanken, P, Bormans, V

Get full text

PMC17 MONITORING OF PHARMACEUTICAL COST OF REIMBURSED MEDICINES BY COMBINING OFFICIAL PHARMACY INVOICE DATA WITH COMMERCIAL IMS SALES DATA by Van Wilder, P, Arickx, F, Van Haeren, E, Bormans, V

Get full text

PHP12 THE BELGIAN REIMBURSEMENT PROCEDURE (BRP):ARE ADDED THE RAPEUTIC VALUE (ATV) AND ICER AFFECTING THE DRUG REIMBURSEMENT DECISION (DRD)? by Verplanken, P, Arickx, F, Bormans, V, Soete, E, Annemans, L, Robays, H, Van Wilder, P

Get full text

PHP13 MARKET AUTHORIZATION (MA) AND REIMBURSEMENT: ANALYSIS OF THE POST-MA TIMELINES AND THE ACCESS TO NEW MEDICINES IN BELGIUM by Arickx, F, Pierlet, M, Soete, E, VanHaeren, E, Verplanken, P, Van Wilder, P

Get full text

PGS7 COST ANALYSIS OF A NEW PROPOSAL FOR REIMBURSEMENT OF PROTON PUMP INHIBITOR TREATMENT OF GASTROESOPHAGEAL REFLUX DISEASE (GERD) IN BELGIUM by Van Wilder, PB, Arickx, F, Vannecke, C, Hiele, M, Verpooten, GA

Get full text